摘要
目的 分析肺癌患者Th1和Th2两类细胞因子的基因表达与转录因子T bet和GATA3表达的相关性 ,探讨黄芪和 (或 )川穹嗪对Th2型肿瘤的干预作用。方法 利用RT PCR技术检测 42例肺癌患者人外周血单个核细胞 (PBMC)中IFNγ、IL 2、IL 4、IL 6、IL 10、T bet、GATA3以及肺癌组织特异性mRNACK19和CEA的表达状况 ;体外加入黄芪和 (或 )川穹嗪后 ,观察IFNγ、IL 4、T bet和GATA3表达的变化情况。结果 42例肺癌患者IFNγ、IL 2、IL 4、IL 6和IL 10的表达频率依次为 4/42 ,5 /42 ,2 7/42 ,2 4/42和 31/42 ;表达强度依次为 0 .10 9,0 .116 ,0 .318,0 .30 6和 0 .372。转录因子T bet和GATA3的表达频率为 6 /42和 34 /42 ,表达强度为 0 .139和 0 .35 9,而且CEA和CK19mRNA阳性的患者中 ,T bet的表达频率和表达强度较低 ,GATA3的表达频率较高 ,表达强度也相应提高 ,表明黄芪和 (或 )川穹嗪能干预这种现象。结论 肺癌患者Th2类细胞因子群谱的高表达与T bet表达降低 ,GATA3表达增高有关 ,黄芪和 (或 )川穹嗪能降低Th2类细胞因子和GATA3的表达 ,提高Th1类细胞因子和T bet的表达。
Objective To study the relation between the expression of transcription factor T-bet/GATA3 and Th1/Th2 type cytokines in peripheral blood mononuclear cells(PBMC) from lung cancer patients and their interference by the traditional Chinese herbal medicine. Methods The gene expression of Th1/Th2 type cytokine IFNγ, IL-2,IL-4, IL-6,IL-10,transcription factor T-bet/GATA3 and tumor tissue specific mRNA CEA, CK19 in PBMC from lung cancer patients were detected by reverse transcription-polymerase chain reaction RT-PCR. Meanwhile, the change of IFNγ, IL-4, T-bet and GATA3 in PBMC before and after being cultured with the traditional Chinese herbal midicine-Astragulus and Tetramethylpyrazine was also observed. Results Predominant expression of Th2 type cytokines was detected in 42 lung cancer patients. The positive rates of IL-4,IL-6,IL-10, IFNγ and IL-2 were 27/42, 24/42, 31/42, 4/42 and 5/42, respectively. But, the positive rates of transcription factor T-bet and GATA3 were 16/42 and 34/42. Moreover, the expression intensity of T-bet was lower in the CEA and CK19 positive patients than the negative ones. On the contrary, the expression intensity of GATA3 was significantly higher in the same patients. Conclusion Predominant expression of Th2 type cytokines may be related to lower expression of T-bet or higher expression of GATA3. This condition can be interfered by the traditional Chinese herbal midicine-Astragulus and Tetramethylpyrazine.
出处
《中华肿瘤杂志》
CAS
CSCD
北大核心
2002年第1期34-37,共4页
Chinese Journal of Oncology
基金
山东省自然科学基金资助项目 (Q98C0 412 )